Richard joined Ipsen in February 2018 and brings more than 25 years of global biopharmaceutical industry experience to the company, with notable achievements for his leadership, vision, and exceptional execution in leading and growing businesses, both in the US and internationally. With a patient-focused mindset and strong track record of successfully building high-performing, customer-centric teams, Richard is responsible for driving continued growth in both the US and Canadian markets across key therapeutics areas of oncology, neurology and rare diseases. Richard serves as a member of the Executive Leadership Team and reports directly to David Meek, CEO of Ipsen.
Richard joined Ipsen from Amgen, where he held varying leadership positions across Europe and North America during his 10 years at the company. In his most recent role as Vice President and General Manager, U.S. Oncology Business Unit, Richard led numerous successful product launches in the oncology and hematology therapeutic areas. Richard also demonstrated his innate leadership ability and passion for employee growth and mentorship through the implementation of a highly successful engagement and people development strategy. Prior to leading the U.S. Oncology Business, Richard served as the Vice President of marketing for the U.S. Oncology Business, General Manager Amgen Germany and General Manager Amgen Central & Eastern Europe. Prior to Amgen, Richard held a number of global leadership positions at Pfizer, including serving as General Manager of Pfizer South Africa and Pfizer Czech Republic. Richard also held a variety of sales, marketing and market access roles with increasing seniority at GlaxoWellcome in Canada.
Richard earned his undergraduate degree in Commerce from the University of Saskatchewan, Canada, and his MBA from the University of Toronto, Canada.
Brad Bailey is responsible for leading Ipsen Biopharmaceuticals’ Oncology and Endocrinology Business Unit, including accelerating portfolio growth to better meet the needs of patients living with oncological and endocrine diseases in North America. Brad brings more than 25 years of biotech and medical device industry expertise spanning sales leadership, marketing, training, operations and market access in oncology. Brad previously served as Ipsen’s Head of U.S. Oncology Sales & Clinical Nurse Educator Team.
Prior to joining Ipsen, Brad held leadership positions at several top life sciences companies. As Principal, Life Sciences Strategy & Transformation, and North America Oncology Lead at Capgemini Consulting, Brad led commercial and operational effectiveness, new product launches, market access, and reimbursement programs for leading biotech firms. Before joining Capgemini Consulting, Brad built a strong track record of success in the oncology space. As Vice President at AVEO Oncology, Brad built a high-performing commercial field organization in preparation for the successful launch of AVEO’s first product in renal cell carcinoma. While at UCB Biopharma, Brad led a launch that quadrupled the company's revenue over the course of three years. In addition to these roles, In addition to these roles, Brad drove commercial performance and organizational productivity at leading companies, such as Stryker Corporation and Pfizer, Inc. where he successfully lead the launch of a blockbuster TKI.
Brad received his undergraduate degree in Business Administration from Clemson University. He has also completed executive coursework at Harvard Business School.
Jennifer Benenson brings more than 20 years of experience as counsel in the pharmaceutical industry to her role as Vice President and North American General Counsel. She is responsible for managing the delivery of legal services to Ipsen business units in North America and advising the leadership team on strategic matters.
Prior to joining Ipsen in 2011, Jennifer served as Vice president and General Counsel at Daiichi Sankyo, Inc. for 10 years, Vice President of Legal Affairs at Dr. Reddy's Laboratories and Vice President, Legal, at Medco Health Solutions Inc.
Jennifer earned her undergraduate degree in Political Science from Brown University, including a year of study at the London School of Economics in political science, and her J.D. from Columbia University School of Law.
Dr. David Cox is responsible for leading medical affairs, post-marketing regulatory affairs, and health outcomes & economics research activities for Ipsen's portfolio in North America. He is a member of Ipsen’s Global Medical Affairs Leadership Team and serves as Ipsen’s representative on the National Pharmaceutical Council’s Board of Directors.
David has spent the majority of his career in global and local medical affairs and clinical development roles, working at Eisai Inc., Bristol-Myers Squibb, Galderma Laboratories and Precept Medical Communications. Most recently, he was the Americas Medical Strategy Lead at Eisai, managing medical directors and Medical Strategy Lead teams and leading the medical affairs strategy for the company’s oncology portfolio in North America and South America. His therapeutic area experience also includes metabolics, cardiovascular and neurology. He has had extensive involvement with product launches, business development, orphan diseases and medical affairs team building/planning.
A biologicchemist by training, David earned his B.A. from Rutgers University and his Ph.D. from the University of Pennsylvania, where he received the Henry Miller Thesis Award for Most Outstanding Doctoral Dissertation for his graduate studies.
Bob serves as Head, North America Government Affairs and Policy, responsible for leading strategy development as well as liaising with government officials, public agencies, industry organizations, policy-setting bodies and third-party advocates regarding legislation, rule making and general health care issues.
Prior to joining Ipsen, Bob was at Sanofi for seven years, most recently serving as the Head of Public Affairs Competitive Intelligence, where he created a novel competitive intelligence group for North American public affairs activities. While at Sanofi, he also led the public policy function for all of Sanofi’s U.S. and Canadian functional units and subsidiaries, covering prescription drugs, R&D, consumer products and animal health.
Prior to Sanofi, Bob worked for Eisai Inc. for 12 years in roles of increasing responsibility. At Eisai, he launched and managed U.S. Federal/State Government Relations and Public Policy. He also led regulatory strategies and government stakeholder engagement for all ex-U.S. jurisdictions in North and South America as the Senior Director, Strategic and Public Policy for the Americas, New Markets Group for Eisai.
Bob earned his M.B.A. from Columbia University Graduate School of Business and his B.A. in Business Economics from Canisius College.
Ron Graybill is the Vice President, Value and Access. In this role,he leads the Strategic Pricing, Account Management, Trade & Distribution, Reimbursement and Patient Services functions. He is an accomplished managed-markets professional with expertise in consultative sales, marketing, pricing strategies, product revitalization and life-cycle management.
Prior to joining Ipsen in 2014, Ron was Vice President, Managed Markets, at Mylan Specialty, where he provided strategic direction to senior executives to ensure long-term growth and profitability for Mylan’s branded, generic and biosimilar businesses. He has also held positions at Bayer HealthCarePharmaceuticals Inc., Novartis and Hoechst Roussel Pharmaceuticals, Inc.
Ron earned his M.B.A. in Finance from Farleigh Dickinson and an undergraduate degree in Economics from Rutgers University – New Brunswick.
Ed Leskauskas is responsible for directing all ethics and compliance activities across North America, drawing on his deep compliance experience and expertise in business strategy, change management and process reengineering.
Prior to joining Ipsen, Ed served as Director, U.S. Pharmaceuticals Compliance and Ethics at Bristol-Myers Squibb, where he was responsible for providing compliance guidance to the business and brand teams, directing compliance integration of acquired entities, leading the implementation of the Bristol-Myers Squibb Corporate Integrity Agreement and managing compliance risk identification and mitigation. Ed also leverages 10 years of experience as a consultant in the pharmaceutical and consumer industries, focused on initiatives such as process reengineering, systems implementation, merchandising, logistics and portfolio management.
Ed holds an M.B.A. from the Mason School of Business at the College of William and Mary and earned his undergraduate degree from Drew University.
Harry brings more than 30 years of business experience and a keen understanding of the pharmaceutical industry to his role as Chief Financial Officer for Ipsen Biopharmaceuticals, Inc. He also leads Ipsen’s North America Shared Services Offerings to all Ipsen North America entities.
Prior to joining Ipsen, Harry held Chief Financial Officer positions at CorMedix Inc. and Mylan Specialty. Harry previously oversaw Finance and Finance Operations for the Sterile Business Unit as a Vice President of Finance at Catalent Pharma Solutions. Before joining Catalent, Harry spent 13 years at Bayer HealthCare Pharmaceuticals Inc., in the roles of Vice President of Business Planning and Administration, Controller and Executive Director for Managed Markets. At Bayer, he implemented an efficient global business unit model for a $2 billion business unit and spearheaded strategic and operative planning, portfolio analysis, business development support and integration.
Harry is a certified public accountant with a B.B.A. in Accounting from Pace University and an M.B.A. from Lehigh University.
Marisol joined Ipsen in April 2017 and has spent over 20 years as a healthcare communications professional, providing expert counsel to support and implement internal and external communications programs across the industry. Marisol sits in Ipsen’s North American headquarters in Basking Ridge, New Jersey, where she leads communications for Ipsen Biopharmaceuticals, Inc., which includes supporting Ipsen Bioscience, Inc. (Cambridge, Massachusetts) and Ipsen Biopharmaceuticals Canada, Inc. (Mississauga, Ontario). She is responsible for driving a ONE Ipsen approach to all communications efforts, including social media engagement and the establishment of a formal advocacy strategy for North America. Additionally, Marisol works cross-functionally with Ipsen colleagues across geographies to achieve communications and organizational objectives for Ipsen worldwide.
Prior to joining Ipsen, Marisol worked at Sanofi for almost 17 years, most recently serving as Associate Vice President of North American Communications for the company’s vaccines division, where she drove strategic communications planning, cultural and organizational change communications for nearly 4,500 employees in North America, crisis management planning and promoting the value of vaccines. Marisol also currently serves on the Board of Junior Achievement of New Jersey.
Marisol earned her M.S. from Boston University’s College of Communication and her B.S. in Mass Communications from Florida International University.
Donald Pearl is responsible for building the neuroscience commercial structure in North America as Ipsen builds on its 25 years of global botulinum toxin clinical experience and pursues a comprehensive and ambitious neurotoxin clinical study program.
Prior to joining Ipsen, Donald served as Vice President, International Sales and Marketing at SkinMedica Inc., an Allergan Company. His 25-year career also includes positions of increasing responsibility in neurology sales and marketing. His experience spans selling pharmaceuticals, surgical devices and topical skincare, leading U.S. and international sales and marketing teams, corporate account management and leading reimbursement policy and access teams as well as sales operations.
Donald earned his B.A. from Rutgers College and a Certificate in Healthcare Management from New York University. He is a retired U.S. Army Infantry Officer with experience at the battalion, brigade and division levels.
Paul has 25 years of experience in the biopharmaceutical industry and serves as Country Manager of Ipsen Biopharmaceuticals Canada. Paul joined Ipsen North America in 2015 as the Vice President, Franchise Head – Endocrinology / Oncology, where he grew franchise net revenue to $247M, a 283% increase over 2014.
Prior to Ipsen, Paul was a management consultant, serving as President of Raven Capital Management, LLC, and working with the boutique agency 1798 Consultants. As a consultant, he engaged with several multinational biopharmaceutical companies on a variety of commercial projects, focused primarily in the therapeutic areas of oncology and neurology. Before working as a management consultant, Paul spent 17 years with Amgen Inc., where he served as a results-driven commercial executive known for his ability to penetrate new markets, launch blockbuster brands, build high-performing teams and deliver results. His expertise lies in the specialty care marketplace.
Paul graduated from Bowling Green State University with a B.S. in Business Administration and an M.B.A. He also spent a brief time serving as an Instructor of Marketing at Bowling Green State University.
NOTE: You are about to leave the Ipsen Biopharmaceuticals, Inc. "Ipsen" website. This link is provided to you as a service to our website visitors. It will take you to another site maintained by a third party who is solely responsible for its content.